191 related articles for article (PubMed ID: 15770521)
1. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
3. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
4. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of BRCA1- and BRCA2-associated breast cancer.
Honrado E; Benítez J; Palacios J
Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
[TBL] [Abstract][Full Text] [Related]
7. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
8. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H
Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814
[TBL] [Abstract][Full Text] [Related]
9. Low expression of bcl-2 in Brca1-associated breast cancers.
Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
[TBL] [Abstract][Full Text] [Related]
10. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
11. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
12. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
13. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D; Nielsen TO; Cheang MC; Foulkes WD
Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
[TBL] [Abstract][Full Text] [Related]
14. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
[TBL] [Abstract][Full Text] [Related]
15. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
[TBL] [Abstract][Full Text] [Related]
16. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
17. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
18. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
19. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
20. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]